GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oramed Pharmaceuticals Inc (NAS:ORMP) » Definitions » Cyclically Adjusted Price-to-FCF

Oramed Pharmaceuticals (Oramed Pharmaceuticals) Cyclically Adjusted Price-to-FCF : (As of Apr. 29, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Oramed Pharmaceuticals Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Oramed Pharmaceuticals Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Oramed Pharmaceuticals's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oramed Pharmaceuticals Cyclically Adjusted Price-to-FCF Chart

Oramed Pharmaceuticals Annual Data
Trend Aug14 Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Oramed Pharmaceuticals Quarterly Data
Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Oramed Pharmaceuticals's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Oramed Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oramed Pharmaceuticals's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oramed Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Oramed Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.



Oramed Pharmaceuticals Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Oramed Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Oramed Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.034/129.4194*129.4194
=-0.034

Current CPI (Dec. 2023) = 129.4194.

Oramed Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201402 -0.163 99.057 -0.213
201405 -0.105 100.373 -0.135
201408 -0.080 100.352 -0.103
201411 -0.138 99.635 -0.179
201502 -0.148 99.032 -0.193
201505 -0.084 100.333 -0.108
201508 -0.090 100.548 -0.116
201511 -0.194 100.135 -0.251
201602 0.184 100.040 0.238
201605 -0.170 101.355 -0.217
201608 0.517 101.617 0.658
201611 0.113 101.829 0.144
201702 -0.220 102.779 -0.277
201705 -0.177 103.256 -0.222
201708 -0.152 103.587 -0.190
201711 -0.192 104.072 -0.239
201802 -0.241 105.052 -0.297
201805 -0.262 106.148 -0.319
201808 -0.285 106.383 -0.347
201811 -0.237 106.338 -0.288
201902 -0.108 106.649 -0.131
201905 -0.210 108.048 -0.252
201908 -0.187 108.245 -0.224
201911 -0.172 108.519 -0.205
202002 -0.204 109.139 -0.242
202005 -0.145 108.175 -0.173
202008 -0.107 109.662 -0.126
202011 -0.272 109.793 -0.321
202102 -0.122 110.968 -0.142
202105 -0.188 113.576 -0.214
202108 -0.186 115.421 -0.209
202111 -0.188 117.269 -0.207
202203 -0.237 121.301 -0.253
202206 -0.219 125.017 -0.227
202209 -0.060 125.227 -0.062
202212 -0.212 125.222 -0.219
202303 -0.144 127.348 -0.146
202306 -0.066 128.729 -0.066
202309 -0.018 129.860 -0.018
202312 -0.034 129.419 -0.034

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Oramed Pharmaceuticals  (NAS:ORMP) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Oramed Pharmaceuticals Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Oramed Pharmaceuticals's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Oramed Pharmaceuticals (Oramed Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
1185 Avenue of the Americas, Third Floor, New York, NY, USA, 10036
Oramed Pharmaceuticals Inc is a pharmaceutical company which is engaged in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The ORMD-0801 is a proprietary product which is an orally ingestible insulin capsule for the treatment of diabetes. Its other product includes Oral Glucagon-like peptide-1 which is an incretin hormone, a type of gastrointestinal hormone that stimulates the secretion of insulin from the pancreas.
Executives
Benjamin Shapiro director 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036
Nadav Kidron director, 10 percent owner 142 W. 57TH ST., NEW YORK NY 10019
Yadin Rozov director 9 TERRACE CIRCLE, ARMONK NY 10504
Miriam Kidron director 2 ELZA STREET, JERUSALEM L3 93706
Michael Rabinowitz officer: Chief Commercial Officer 1185 AVENUE OF THE AMERICAS, THIRD FLOOR, NEW YORK NY 10036
Arie Mayer director MORAN 16, KFAR SABA L3 4428890
Netanel Derovan officer: Chief Legal Officer 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036
David Silberman officer: Chief Financial Officer 20 MAMILLA AVENUE, JERUSALEM L3 9414904
Kevin Rakin director 36 CHURCH LANE, WESTPORT CT 06880
Michael Rabinowitz officer: Chief Commercial Officer MAXIM GROUP, LLC, 405 LEXINGTON AVENUE, NEW YORK NY 10174
Leonard Sank director 3 BLAIR ROAD, CAPE TOWN T3 8005
Gao Xiaoming director 11F. NO. 266 HANKOU ROAD, HUANGPU DISTRICT, SHANGHAI F4 2000001
Avraham Gabay officer: CFO, Treasurer and Secretary 2/4 HIGH-TECH PARK, P.O. BOX 39098, JERUSALEM L3 91390
Mark Daniel Hasleton officer: VP Business Development 13, HIBAT ZION, RAANANA, RAANANA L3 4338111
Aviad Friedman director HADASSA 6, TEL AVIV L3 6451306